M A Blajchman

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop
    Morris A Blajchman
    McMaster University, Hamilton, Ontario, Canada
    Transfusion 52:1363-78. 2012
  2. ncbi Clinical trial opportunities in Transfusion Medicine: proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium
    Morris A Blajchman
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Transfus Med Rev 24:259-85. 2010
  3. ncbi Immunomodulation and blood transfusion
    Morris A Blajchman
    Department of Pathology, McMaster University, and Canadian Blood Services, Hamilton, Ontario, Canada
    Am J Ther 9:389-95. 2002
  4. ncbi Bacterial contamination of cellular blood components: risks, sources and control
    M A Blajchman
    McMaster University, Ontario, Canada
    Vox Sang 87:98-103. 2004
  5. ncbi Substitutes and alternatives to platelet transfusions in thrombocytopenic patients
    M A Blajchman
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 1:1637-41. 2003
  6. ncbi Novel platelet products, substitutes and alternatives
    M A Blajchman
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfus Clin Biol 8:267-71. 2001
  7. ncbi Red blood cell transfusion strategies
    M A Blajchman
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfus Clin Biol 8:207-10. 2001
  8. ncbi Improving the bacteriological safety of platelet transfusions
    Morris A Blajchman
    Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, HSC 2N34, Hamilton, Notario, Canada L8N 3Z5
    Transfus Med Rev 18:11-24. 2004
  9. ncbi Proceedings of a consensus conference: the screening of blood donors for variant CJD
    Morris A Blajchman
    Canadian Blood Services, Hamilton, Ontario, Canada
    Transfus Med Rev 18:73-92. 2004
  10. ncbi Incidence and significance of the bacterial contamination of blood components
    M A Blajchman
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Dev Biol (Basel) 108:59-67. 2002

Detail Information

Publications59

  1. ncbi The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop
    Morris A Blajchman
    McMaster University, Hamilton, Ontario, Canada
    Transfusion 52:1363-78. 2012
    ....
  2. ncbi Clinical trial opportunities in Transfusion Medicine: proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium
    Morris A Blajchman
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Transfus Med Rev 24:259-85. 2010
    ..The various proposals identified many opportunities for clinical trial research and most importantly underscored the ongoing need for well-developed evidence-based clinical trial research in the field of Transfusion Medicine...
  3. ncbi Immunomodulation and blood transfusion
    Morris A Blajchman
    Department of Pathology, McMaster University, and Canadian Blood Services, Hamilton, Ontario, Canada
    Am J Ther 9:389-95. 2002
    ..Further studies, both basic and applied, to establish the clinically relevant manifestations of TRIM as well as the mechanism(s) are urgently required...
  4. ncbi Bacterial contamination of cellular blood components: risks, sources and control
    M A Blajchman
    McMaster University, Ontario, Canada
    Vox Sang 87:98-103. 2004
  5. ncbi Substitutes and alternatives to platelet transfusions in thrombocytopenic patients
    M A Blajchman
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 1:1637-41. 2003
    ..However, safety and efficacy must be demonstrable in preclinical studies and clinical trials, before novel platelet concentrates, platelet substitutes and alternatives to platelets can be used in patients with thrombocytopenia...
  6. ncbi Novel platelet products, substitutes and alternatives
    M A Blajchman
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfus Clin Biol 8:267-71. 2001
    ..However, safety and efficacy must be demonstrated in pre-clinical and phase I to III clinical trials before these novel agents, substitutes and alternatives can be used clinically for patients with thrombocytopenia...
  7. ncbi Red blood cell transfusion strategies
    M A Blajchman
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfus Clin Biol 8:207-10. 2001
    ..Nonetheless, the available data, together with detailed information about alternatives to blood product transfusions, will enable physicians to improve outcomes in transfused patients...
  8. ncbi Improving the bacteriological safety of platelet transfusions
    Morris A Blajchman
    Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, HSC 2N34, Hamilton, Notario, Canada L8N 3Z5
    Transfus Med Rev 18:11-24. 2004
    ..All of these approaches, either collectively or individually, hold considerable promise that the prevalence of adverse events associated with bacteria in platelet products will decline significantly in the very foreseeable future...
  9. ncbi Proceedings of a consensus conference: the screening of blood donors for variant CJD
    Morris A Blajchman
    Canadian Blood Services, Hamilton, Ontario, Canada
    Transfus Med Rev 18:73-92. 2004
    ..This contentious issue is of potential considerable importance to transfusion medicine personnel worldwide, as well as to future recipients of allogeneic blood components...
  10. ncbi Incidence and significance of the bacterial contamination of blood components
    M A Blajchman
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Dev Biol (Basel) 108:59-67. 2002
    ..As a result of the increased recognition that such transfusion-associated episodes can occur, a variety of measures have been proposed to try to prevent and/or control the risk of transfusion-associated septic reactions...
  11. ncbi The clinical benefits of the leukoreduction of blood products
    M A Blajchman
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    J Trauma 60:S83-90. 2006
    ....
  12. ncbi The top ten list of randomized controlled trials in transfusion medicine
    M A Blajchman
    McMaster University, Department of Pathology, Hamilton, Ontario, Canada
    Vox Sang 87:193-6. 2004
  13. ncbi Landmark studies that have changed the practice of transfusion medicine
    Morris A Blajchman
    Departments of Pathology and Medicine, McMaster University, 1200 Main Street West, HSC 2N34, Hamilton, Ontario, Canada L8N 3Z5
    Transfusion 45:1523-30. 2005
  14. ncbi Transfusion immunomodulation or TRIM: what does it mean clinically?
    M A Blajchman
    Department of Pathology, Canadian Blood Services Hamilton, McMaster University, Ontario, Canada
    Hematology 10:208-14. 2005
    ..These latter data suggest that allogeneic blood product transfusions, containing leukocytes, are associated with an increased risk both for mortality, and organ dysfunction in recipients...
  15. ncbi Bacterial detection of platelets: current problems and possible resolutions
    Morris A Blajchman
    McMaster University and Canadian Blood Services, Hamilton, Ontario, Canada
    Transfus Med Rev 19:259-72. 2005
    ....
  16. ncbi Protecting the blood supply from emerging pathogens: the role of pathogen inactivation
    M A Blajchman
    Department of Pathology and Molecular Medicine, McMaster University, HSC 4N67 Hamilton, ON, Canada
    Transfus Clin Biol 16:70-4. 2009
    ..However, in order for pathogen inactivation technologies to become widely accepted, they must be shown to be both cost effective and not associated with new risks to recipients!..
  17. ncbi In vitro evaluation of prestorage pooled leukoreduced whole blood-derived platelets stored for up to 7 days
    N M Heddle
    Department of Medicine, McMaster University, Canadian Blood Services, Hamilton, Ontario, Canada
    Transfusion 45:904-10. 2005
    ..The in vitro quality of pre-storage pooled PLTs stored for up to 7 days was assessed...
  18. ncbi o-raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits
    D H Lee
    Departments of Medicine and Pathology, Queen s University, Kingston, Ontario, Canada
    Blood 96:3630-6. 2000
    ..These data suggest that CLHb may shift the thromboregulatory balance toward clot formation, resulting in decreased bleeding in anemic and thrombocytopenic rabbits and possibly increasing arterial thrombogenicity in normal rabbits...
  19. ncbi The procoagulant state of the VX-2 tumor in rabbit lung in vivo--relative accumulation of fibrinogen, prothrombin, plasminogen, antithrombin and heparin cofactor II within the tumor
    M W Hatton
    Department of Pathology and Molecular Medicine, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada
    Thromb Haemost 82:1694-702. 1999
    ..From the net fluxes of these proteins, the profile of chronic hemostasis associated with the VX-2 tumor was shown to differ markedly from the hemostatic response that occurs after an acute vascular injury...
  20. ncbi Rapid in vivo induction of leukocyte tissue factor mRNA and protein synthesis following low dose endotoxin administration to rabbits
    T C Brutzki
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Hematol J 2:188-95. 2001
    ..Moreover, all-trans retinoic acid may be effective in modulating in vivo the TF transcription induced by endotoxin...
  21. ncbi Metabolism of rabbit plasma-derived factor VII in relation to prothrombin in rabbits
    M W Hatton
    Department of Pathology and Molecular Medicine, McMaster University Health Sciences Centre, 1200 Main St West, Hamilton, Ontario, Canada, L8N 3Z5
    Am J Physiol Endocrinol Metab 281:E507-15. 2001
    ..These results indicate that, compared with prothrombin, factor VII in the healthy rabbit circulates as a relatively long-lived protein. This behavior does not reflect that reported for factor VII in the human circulation...
  22. ncbi In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers
    Donald M Arnold
    Canadian Blood Services, Hamilton, Ontario, Canada
    Transfusion 46:257-64. 2006
    ..The reasons for this effect are not clear. These results may not apply to all apheresis and PRP methods of platelet preparation...
  23. ncbi Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?
    P C Hebert
    Critical Care Programs, University of Ottawa, Ottawa, ON, Canada
    Crit Care Med 29:227-34. 2001
    ..To compare a restrictive red blood cell transfusion strategy with a more liberal strategy in volume-resuscitated critically ill patients with cardiovascular disease...
  24. ncbi Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial
    N M Heddle
    Department of Medicine and Pathology and Molecular Medicine, McMaster University, and the Canadian Blood Services, Hamilton, Ontario, Canada
    Transfusion 45:896-903. 2005
    ..This study evaluated the in vivo effect of the prestorage pooling of PLTs stored for up to 5 days, by assessing the corrected count increment (CCI) 18 to 24 hours after transfusion of the product...
  25. ncbi Platelet substitutes and novel platelet products
    D H Lee
    Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, HSC 2N34, Hamilton, Ontario, L8N 3Z5, Canada
    Expert Opin Investig Drugs 9:457-69. 2000
    ..Safety and efficacy, however, must be demonstrated in preclinical and Phase I - III clinical trials, before these novel agents can be used clinically for patients with thrombocytopenia...
  26. ncbi CD200-dependent and nonCD200-dependent pathways of NK cell suppression by human IVIG
    David A Clark
    Department of Medicine, McMaster University, 1200 Main St West, Hamilton, ON L8N 3Z5, Canada
    J Assist Reprod Genet 25:67-72. 2008
    ..CD200 acts by binding to CD200 receptors (C200R). The objective of this study was to determine if CD200-dependent NK suppression by IVIG involved direct binding of IVIG-associated CD200 molecules to CD200R on NK cells...
  27. ncbi A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation
    Kathryn E Webert
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfusion 48:81-91. 2008
    ..Anemia may be an important factor contributing to an increased risk of bleeding, particularly in patients with thrombocytopenia...
  28. ncbi Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies
    Kathryn E Webert
    Medical, Scientific, and Research Affairs, Canadian Blood Services, Hamilton, Edmonton and Toronto, Canada
    Transfus Med Rev 22:1-34. 2008
    ..These proceedings are provided to make available to the transfusion medicine community the considerable amount of important information presented at this consensus conference...
  29. ncbi Consumption of plasma factor VII in a rabbit model of non-overt disseminated intravascular coagulation
    Bryan J Clarke
    Department of Pathology and Molecular Medicine, HSC 4N65, McMaster University, 1200 Main St West, L8N 3Z5, Hamilton, Ontario, Canada
    Thromb Res 108:329-34. 2002
    ..J. 2 (2001) 188]. In the present study, we demonstrate that the leukocyte TF expressed has procoagulant activity leading to a rapid decline in the concentration of factor VII (FVII) in rabbit plasma...
  30. ncbi A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets
    Nancy M Heddle
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Transfusion 42:556-66. 2002
    ..This study evaluates the effectiveness of plasma removal and two methods of prestorage WBC reduction for preventing acute reactions to platelets...
  31. ncbi A prospective study evaluating the lowering of hemoglobin standards for blood donors
    A M Ali
    Canadian Red Cross Blood Transfusion Service, St Joseph s Hospital, Hamilton, Ontario, Canada
    Transfusion 29:268-72. 1989
    ..Group II were donors who did not meet the existing Hb criteria but satisfied the newly derived standards. Group III were donors deferred even by the new Hb standards.(ABSTRACT TRUNCATED AT 250 WORDS)..
  32. ncbi Bacterial contamination of platelet concentrates: incidence, significance, and prevention
    M A Blajchman
    Department of Pathology and Medicine, McMaster University, and Canadian Blood Services, Hamilton, Ontario, Canada
    Semin Hematol 38:20-6. 2001
    ....
  33. ncbi Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions
    Paul C Hebert
    University of Ottawa Centre for Transfusion Research, and Clinical Epidemiology Program of the Ottawa Health Research Institute, Ottawa, Ontario, Canada
    JAMA 289:1941-9. 2003
    ..A number of countries have implemented a policy of universal leukoreduction of their blood supply, but the potential role of leukoreduction in decreasing postoperative mortality and infection is unclear...
  34. ncbi Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage
    Donald M Arnold
    Canadian Blood Services, Ontario, Canada
    Transfusion 44:1361-6. 2004
    ..CONCLUSION: Hypotensive reactions can occur with blood products that are LR before storage and non-LR ANH. An inherent defect in the metabolism of kinins may be a risk factor for the development of hypotensive transfusion reactions...
  35. ncbi The continuing risk of transfusion-transmitted infections
    Morris A Blajchman
    McMaster University, Hamilton, ON, Canada
    N Engl J Med 355:1303-5. 2006
  36. ncbi Partial deletion of an antithrombin III allele in a kindred with a type 1 deficiency
    F Fernandez-Rachubinski
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Blood 80:1476-85. 1992
    ..The breakpoint in the partially deleted allele is 480 bp upstream from the 5' boundary of exon 3. No significant homology was found between the 0.7-kb sequence upstream to the breakpoint of the mutant allele and known human sequences...
  37. ncbi Interspecies exchange mutagenesis of the first epidermal growth factor-like domain of human factor VII
    V Williamson
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 3:1250-6. 2005
    ..We conclude that substitution of selected amino acid residues of the FVII EGF1 domain facilitated the creation of human rFVII chimeric proteins with both enhanced biological activity and increased affinity for TF...
  38. ncbi Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and interacts with thrombin-antithrombin complexes
    M J Wells
    Department of Pathology, McMaster University, Hamilton, Ontario L8N 3Z5, Canada
    J Biol Chem 272:28574-81. 1997
    ..Biol. Chem. 271, 25684-25691) and CK1 cell membrane surface expression (Schmaier, A. H. (1997) Thromb. Hemostasis 78, 101-107), indicate a novel role for these proteins as putative cellular receptors or cofactors to cellular receptors...
  39. ncbi Molecular cloning and expression of rabbit heparin cofactor II: a plasma thrombin inhibitor highly conserved between species
    W P Sheffield
    Canadian Red Cross Society Blood Services, Hamilton, Ontario
    Thromb Haemost 71:778-82. 1994
    ..The remarkable degree of homology observed between rabbit HCII and its human counterpart, indicating a high degree of conservation of structure through evolution, suggests an important function of HCII in hemostasis...
  40. ncbi The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants
    Haresh Kirpalani
    Pediatrics and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    J Pediatr 149:301-307. 2006
    ..CONCLUSIONS: In extremely low birth weight infants, maintaining a higher hemoglobin level results in more infants receiving transfusions but confers little evidence of benefit...
  41. ncbi Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen
    David A Clark
    Department of Medicine, Immunology and Inflammation Program, McMaster University, Hamilton, Ontario, Canada
    Transfusion 48:814-21. 2008
    ....
  42. ncbi The age of red blood cells in premature infants (ARIPI) randomized controlled trial: study design
    Dean Fergusson
    Ottawa Health Research Institute, Ottawa, Ontario, Canada
    Transfus Med Rev 23:55-61. 2009
    ..The Age of Red Blood Cells in Premature Infants (ARIPI) trial is registered at the US National Institutes of Health (ClinicalTrials.gov) no. NCT00326924 and current controlled trials ISRCTN65939658...
  43. ncbi Proceedings of a consensus conference: towards an understanding of TRALI
    Mindy Goldman
    Canadian Blood Services, Medical, Scientific and Research Affairs, Ottawa, Ontario K1G 4J5, Canada
    Transfus Med Rev 19:2-31. 2005
    ....
  44. ncbi Transfusion-related acute lung injury
    Kathryn E Webert
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfus Med Rev 17:252-62. 2003
    ..In this report, what is known about TRALI is summarized and some of the areas in which knowledge and/or consensus are currently lacking are identified...
  45. ncbi Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin
    Donald M Arnold
    Canadian Blood Services, Hamilton, Ontario, Canada
    Anesth Analg 102:731-7. 2006
    ..Further high-quality trials with clinically important outcomes may be warranted before aprotinin can be routinely recommended in this population...
  46. ncbi Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity
    Mark W C Hatton
    Department of Pathology and Molecular Medicine, McMaster University Health Sciences Centre, 1200 Main Street W, Hamilton, Ontario, Canada L8N 3Z5
    J Lab Clin Med 143:241-54. 2004
    ....
  47. ncbi Molecular basis of inherited human antithrombin deficiency
    M A Blajchman
    Canadian Red Cross Society Blood Transfusion Service, Hamilton, Ontario
    Blood 80:2159-71. 1992
    ..Finally, such knowledge might, in the foreseeable future, lead to the production of AT molecules that are specifically genetically engineered to be of use in a variety of clinical situations...
  48. ncbi Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo
    L Liu
    Canadian Red Cross Society, Blood Services, Hamilton, Canada
    Thromb Haemost 73:405-12. 1995
    ..Thus, heparin cofactor II normally inactivates thrombin in vivo, with its role increasing in conditions associated with high levels of heparin cofactor II and/or dermatan sulfate...
  49. ncbi Complete nucleotide sequence of the cDNA encoding rabbit coagulation factor VII
    A B Brothers
    Department of Pathology, McMaster University, Hamilton, Ontario, Canada
    Thromb Res 69:231-8. 1993
    ..Mature circulating rabbit factor VII is predicted to contain 404 amino acids, two less than its human counterpart and three less than bovine factor VII...
  50. ncbi Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review
    Craig D Ainsworth
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Transfus Med Rev 23:155-9. 2009
    ..Passenger lymphocyte syndrome-associated hemolysis is occasionally severe as in our case, but can be effectively treated with compatible RBC transfusions...
  51. ncbi Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors
    Mark W C Hatton
    Department of Pathology and Molecular Medicine, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada
    J Lab Clin Med 139:316-23. 2002
    ....
  52. ncbi Transfusion-related acute lung injury
    Kathryn E Webert
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Curr Opin Hematol 12:480-7. 2005
    ..SUMMARY: In this report, what is known about transfusion-related acute lung injury is summarized with particular emphasis on recent studies. Some of the areas in which knowledge and/or consensus are currently lacking are identified...
  53. ncbi Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits
    Mikael Tranholm
    Pharmacology Research 5, Pharmacology Research and Development, Novo Nordisk A S, Novo Nordisk Park, DK 2760 Maaloev, Denmark
    Thromb Res 109:217-23. 2003
    ..These data demonstrate the haemostatic efficacy of rFVIIa in a rabbit model of severe thrombocytopenia. Clinical trials will be needed to further explore the potential of NovoSeven as a haemostatic agent in thrombocytopenic patients...
  54. ncbi Transfusion-related immunomodulation (TRIM): an update
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, University of Ottawa, Faculty of Medicine, Canada
    Blood Rev 21:327-48. 2007
    ....
  55. ncbi Protecting the blood supply from emerging pathogens: the role of pathogen inactivation
    Jean Pierre Allain
    Department of Hematology, University of Cambridge, Cambridge Blood Centre, UK
    Transfus Med Rev 19:110-26. 2005
    ..However, widespread use of a pathogen inactivation technology can only be realized when proven safe and efficacious and not cost-prohibitive...
  56. ncbi Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants
    Dean Fergusson
    Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec
    JAMA 289:1950-6. 2003
    ..Premature infants, given their immature immune state, may be uniquely predisposed to the effects of transfused leukocytes...
  57. ncbi Randomized trials in patients with blunt and penetrating trauma
    Kathryn E Webert
    J Trauma 60:242-3; author reply 243-4. 2006
  58. ncbi Passive transfer of peanut hypersensitivity by fresh frozen plasma
    Donald M Arnold
    Arch Intern Med 167:853-4. 2007
  59. ncbi A comparison of aprotinin and lysine analogues in high-risk cardiac surgery
    Dean A Fergusson
    Ottawa Health Research Institute, Ottawa, Canada
    N Engl J Med 358:2319-31. 2008
    ..We sought to determine whether aprotinin was superior to either tranexamic acid or aminocaproic acid in decreasing massive postoperative bleeding and other clinically important consequences...